Hormone patterns during bromocriptine-induced pregnancy in hyperprolactinemic patients

Area of Science:

• Reproductive Endocrinology
• Obstetrics
• Endocrinology

Background:

• Hyperprolactinemia can affect fertility and pregnancy outcomes.
• Previous treatments like surgery or radiation may not fully resolve hyperprolactinemia.
• Bromocriptine is used to manage hyperprolactinemia during pregnancy.

Purpose of the Study:

• To investigate the impact of bromocriptine-induced pregnancies in hyperprolactinemic women on key pregnancy hormones.
• To assess fetoplacental endocrine function in the presence of elevated prolactin levels during pregnancy.

Main Methods:

• Studied plasma prolactin (PRL) and human placental lactogen (HPL), and urinary estriol and pregnanediol.
• Included 10 hyperprolactinemic women undergoing bromocriptine-induced pregnancies.
• Monitored hormone levels after bromocriptine withdrawal and at term.

Main Results:

• Prolactin levels increased significantly after bromocriptine withdrawal, exceeding normal pregnancy levels in some cases.
• Elevated pathological PRL levels at term were observed in 3 subjects with sellar alterations.
• Estriol, pregnanediol, and HPL levels remained normal in all subjects.

Conclusions:

• Elevated prolactin levels during pregnancy, even those higher than normal, do not appear to compromise fetoplacental endocrine function.
• Bromocriptine management allows for successful pregnancies in hyperprolactinemic women without adverse effects on key pregnancy hormones.